Elbírált közlemények:

A tanszék munkatársainak valamennyi (a hazai és nemzetközi kollaborációban megvalósított kutatómunkát is tükröző) in extenso publikációi a 2000-2001, 2001-2002, 2002-2003, 2003-2004, 2004-2005, 2005-2006, és a leendő 2006-2007 évkönyvek adatai alapján.

A közlemények bibliográfia adatai és amennyiben van, impakt faktora:

1. Papp, Z., Édes, I. A myocardialis ischaemia és reperfúzió patofiziológiája. Lege Artis Medicinae 10, 501-511, 2000.

2. Papp, Z., Barta, J., Stienen, G.J.M.: Troponin I degradation and myocardial stunning. Circulation 104, e157-e157, (letter) 2001. 10,517

3. Tóth, A, Kedei, N., Szabó, T., Wang Y., Blumberg, P.M.: Thapsigargin binds to and inhibits the cloned vanilloid receptor-1. Biochem. Biophys. Res. Commun. 293, 777-782, 2002. 2,935

4. Van der Velden, J. ,Boontje, N.M., Papp, Z., Klein, L.J., Visser, F.C., de Jong, J.W. Owen, V.J., Burton, P.B.J., Stienen, G.J.M. Calcium sensitivity of force in human ventricular cardiomyocytes from donor and failing hearts. Bas. Res. Cardiol. 97 Suppl.1, I/118-I/126, 2002. 1,994

5. Wang, Y., Szabo, T., Welter, J.D., Toth, A., Tran, R, Lee, J, Kang, S.U., Suh, Y.G., Blumberg, P.M., Lee, J.: High affinity antagonists of the vanilloid receptor. Mol. Pharmacol. 62, 947-956. 2002. 5,480

6. Barta, J., Tóth, A., Jaquet, K., Redlich, A., Édes, I., Papp, Z. Calpain-1-dependent degradation of troponin I mutants found in familial hypertrophic cardiomyopathy. Mol. Cell. Biochem. 251, 83-88, 2003. 1,763

7. Lee, J., Kang, M., Shin, M., Kim, J.M., Kang, S.U., Lim, J.O., Choi, H.K., Suh, Y.G., Park, H.G., Oh, U., Kim, H.D., Park, Y.H., Ha, H.J., Kim, Y.H., Toth, A., Wang, Y., Tran, R., Pearce, L.V., Lundberg, D.J., Blumberg, P.M.: N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]-thiourea analogues: novel potent and high affinity antagonists and partial antagonists of the vanilloid receptor. J. Med. Chem. 46, 3116-3126, 2003. 4,820

8. Toth, A., Kedei, N., Wang, Y., Blumberg, P.M.: Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci. 73, 487-498, 2003. 1,944

9. van der Velden, J., Papp, Z., Zaremba, R., Boontje, N.M., de Jong, J.W., Owen, V.J., Burton, P.B.J., Goldmann, P., Jaquet, K., Stienen, G.J.M.: Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc. Res. 57, 37-47, 2003. 5,164

10. van der Velden, J. Papp, Z., Boontje, N.M., Zaremba, R., de Jong, J.W., Janssen, P.M.L., Hasenfuss, G., Stienen, G.J.M. The effect of myosin light chain 2 dephosphorylation on Ca2+-sensitivity of force is enhanced in failing human hearts. Cardiovasc. Res. 57, 505-524, 2003. 5,164

11. Wang, Y, Toth, A., Tran, R., Szabo, T., Welter, J.D., Blumberg, P.M., Lee, J., Kang, S.U., Lim, J.O., Lee, J.: High-affinity partial agonists of the vanilloid receptor. Mol. Pharmacol. 64, 325-333, 2003. 5,650

12. Bodi A., Szilagyi S., Edes I. Papp Z.: The cardiotomic effects of levosimendan in guinea pig hearts are modulated by -adrenergic stimulation. Gen. Phys. Biophys. 22, 313-327, 2003. 0,794

13. van der Velden J., Papp Z., Boontje N.M., Zaremba R., de Jong J.W., Janssen P.M., Hasenfuss G., Stienen G.J.M. Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium. Adv. Exp. Med. Biol. 538, 3-15, 2003. 0,642

14. Bagi Z., Toth E., Koller A., Kaley G.: Microvascular dysfunction after transient high glucose is caused by superoxide-dependent reduction in the bioavailability of NO and BH(4). Am. J. Physiol. 287, H626-H633, 2004. 3,539

15. Brodie C., Steinhart R., Kazimirsky G., Rubinfeld H., Hyman T., Ayres J.N., Hur G.M., Toth A., Yang D., Garfield S.H., Stone J.C., and Blumberg P.M. PKCdelta associates with and is involved in the phosphorylation of RasGRP3 in response to phorbol esters. Mol. Pharmacol. 66, 76-84, 2004. 5,080

16. Lee J., Kim S.Y., Lee J., Kang M., Kil M.J., Choi H.K., Jin M.K., Wang Y., Toth A., Pearce L.V., Lundberg D.J., Tran R., Blumberg P.M.: Analysis of structure-activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism. Bioorg. Med. Chem. 12, 3411-3420, 2004. 2,018

17. Lee J., Kim S.Y., Park S., Lim J.O., Kim J.M., Kang M., Lee J., Kang S.U., Choi H.K., Jin M.K., Welter J.D., Szabo T., Tran R., Pearce L.V., Toth A., Blumberg P.M.: Structure-activity relationships of simplified resiniferatoxin analogues with potent VR1 agonism elucidates an active conformation of RTX for VR1 binding. Bioorg. Med. Chem. 12, 1055-1069, 2004. 2,018

18. Lee J., Kang S.U., Lim J.O., Choi H.K., Jin M., Toth A., Pearce L.V., Tran R., Wang Y., Szabo T., Blumberg P.M.: N-[4-(Methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structure-activity relationships for the 'C-Region'. Bioorg. Med. Chem. 12, 371-385, 2004. 2,018

19. Lee J., Kang S.U., Choi H.K., Lee J., Lim J.O., Kil M.J., Jin M.K., Kim K.P., Sung J.H., Chung S.J., Ha H.J., Kim Y.H., Pearce L.V. , Tran R., Lundberg D.J., Wang Y., Toth A., Blumberg P.M.: Analysis of structure-activity relationships for the 'B-region' of N-(3-acyloxy-2-benzylpropyl)-N(')-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: discovery of an N-hydroxythiourea analogue with potent analgesic activity. Bioorg. Med. Chem. Lett. 14, 2291-2297, 2004. 2,333

20. Papp Z., van der Velden J., Borbely A., Edes I., Stienen G.J.M.: Effects of Ca2+-sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts. J. Muscle Res. Cell. Motil. 25, 219-224, 2004. 1,721

21. Szilágyi S., Pollesello P., Levijoki J., Kaheinen P., Haikala H., Edes I., Papp Z.: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur. J. Pharmacol. 486, 67-74, 2004. 2,432

22. Mohácsi, A., Lizanecz, E., Édes, I., Czuriga, I.: A szöveti angiotenzinkonvertáló enzim szerepe a cardiovascularis betegségekben. Lege Artis Medicinae 12, 843-849, 2004. -

23. Toth A., Blumberg P.M., Chen Z., Kozikowski A.P.: Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. Mol. Pharmacol. 65, 282-291, 2004. 5,080

24. Wang, Y., Kedei, N., Wang, M., Wang, Q.J., Huppler, A.R., Toth, A., Tran, R., Blumberg, P.M.: Interaction between protein kinase Cmu and the vanilloid receptor type 1. J. Biol. Chem. 279, 53674-53682, 2004. 6,355

25. Koller, A., Bagi, Z.: Nitric oxide and hydrogen peroxide contribute to the reactive dilation of isolated coronary arterioles. Am. J. Physiol. Heart Circ. Physiol. 287, H2461-H2467, 2004. 3,539

26. Pemberton, C.J., Tokola, H., Bagi, Z., Koller, A., Pöntinen, J., Ola, A., Vuolteenaho, O., Szokodi, I., Ruskoaho, H.: Ghrelin induces vasoconstriction in the rat coronary vasculature without altering cardiac peptide secretion. Am. J. Physiol. Heart Circ. Physiol. 287, H1522-H1529, 2004. 3,539

27. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Cancer Res. 64(9):3243-55, 2004. 7,690

28. Cseko C, Bagi Z, Koller A. Biphasic effect of hydrogen peroxide on skeletal muscle arteriolar tone via activation of endothelial and smooth muscle signaling pathways. J Appl Physiol. 97:1130-1137, 2004. 2,824

29. Bagi, Z., Frangos, J.A., Yeh, J.C., White, C.R., Kaley, G., Koller, A.: PECAM-1 mediates NO-dependent dilation of arterioles to high temporal gradients of shear stress. Arterioscler. Thromb. Vasc. Biol. 25, 1590-1595, 2005. 7,053

30. Bagi, Z, Erdei, N, Toth, A, Li, W., Hintze, T.H., Koller, A., Kaley, G.: Type 2 diabetic mice have increased arteriolar tone and blood pressure. Enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler. Thromb. Vasc. Biol. 5, 1610-1616, 2005. 7,053

31. Borbely, A., van der Velden, J., Papp, Z., Bronzwaer, J.G.F., Edes, I., Stienen, G.J.M., Paulus, W.J. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111, 774-781, 2005. 11,632

32. Borbely, A., Toth, A., Edes, I., Virag, L., Papp J.G., Varro, A., Paulus, W.J., van der Velden, J., Stienen, G.J.M., Papp, Z.: Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells. Cardiovasc. Res. 67, 225-233. 2005. 5,283

33. Cazorla, O., Szilagyi, S., Le Guennec, J.Y., Vassort, G., Lacampagne, A. Transmural stretch-dependent regulation of contractile properties in rat heart and its alteration after myocardial infarction. FASEB J. 19, 88-90, 2005. 7,064

34. Papp, Z., Csapó, K., Pollesello, P., Haikala, H., Édes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc. Drug Rev. 23, 71-98, 2005. 2,122

35. Toth, A., Boczan, J., Kedei, N., Lizanecz, E., Bagi, Z., Papp, Z., Edes, I., Csiba L, Blumberg PM.: Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain. Res. 135, 162-168, 2005. 1,585

36. Toth, A., Wang, Y., Kedei, N., Tran, R., Pearce, L.V., Kang, S.U., Jin, M.K., Choi, H.K., Lee, J., Blumberg, P.M. Different vanilloid agonists cause different patterns of calcium response in CHO cells heterologously expressing rat TRPV1. Life Sci. 76, 2921-2932, 2005. 2,512

37. Barta, J., Tóth, A., Vaszily M., Papp, J,Gy, Varró, A., Édes I., Papp, Z. Calpain-1 induced proteolysis of human myofibrillar proteins. Mol. Cell. Biochem. 278, 1-8, 2005. 1,681

38. Szilágyi, S., Pollesello, P., Levojoki, J., Haikala, H., Bak., I., Tósaki Á., Borbély, A., Édes, I. Papp, Z. Two positive inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J. Cardiovasc. Pharmacol. 46, 369-376, 2005. 1,313

39. Lee J, Kang SU, Kil MJ, Shin M, Lim JO, Choi HK, Jin MK, Kim SY, Kim SE, Lee YS, Min KH, Kim YH, Ha HJ, Tran R, Welter JD, Wang Y, Szabo T, Pearce LV, Lundberg DJ, Toth A, Pavlyukovets VA, Morgan MA, Blumberg PM. Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists. Bioorg Med Chem Lett. 15, 4136-4142, 2005. 2,478

40. Lee J, Jin MK, Kang SU, Kim SY, Lee J, Shin M, Hwang J, Cho S, Choi YS, Choi HK, Kim SE, Suh YG, Lee YS, Kim YH, Ha HJ, Toth A, Pearce LV, Tran R, Szabo T, Welter JD, Lundberg DJ, Wang Y, Lazar J, Pavlyukovets VA, Morgan MA, Blumberg PM. Analysis of structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists. Bioorg Med Chem Lett. 15, 4143-4150, 2005 2,478

41. J. Machackova, J. Barta , N.S. Dhalla: Molecular Defects in Cardiac Myofibrillar Proteins due to Thyroid Hormone Imbalance and Diabetes. Can. J Physiol. Pharmacol. 83, 1071-1091, 2005. 1,522

42. Cazorla, O., Szilagyi, S., Vignier, N., Salazar, G., Kramer, E., Vassort, G., Carrier, L., Lacampagne, A. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc. Res. 69, 370-380, 2006. 5,826

43. Kaheinen, P., Pollesello, P., Hertelendi, Z., Borbély, A., Szilagyi, Sz., Édes, I., Levijoki, J., Haikala, H., Papp, Z. The positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Bas. Clin. Pharmacol.Toxicol. 98, 74-78, 2006. 1,788

44. Van der Velden, J., Narolska, N.A., Boontje, N.M., Borbély, A., Zaremba, R., Bronzwaer, J.G.F., Papp, Z., Jaquet, K., Paulus, W.J., Stienen G.J.M. Functional effects of protein kinase C-mediated myofilament phosphorylation in human myocardium. Cardiovasc. Res. 69:876-887, 2006. 5,826

45. Lizanecz, E., Bagi, Z., Pasztor, T.E., Papp, Z., Edes, I., Kedei, N., Blumberg, P.M., Toth, A. Phosphorylation dependent desensitization of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in CHO-TRPV1 cells by anandamide. Mol. Pharmacol. 69, 1015-1023, 2006. 4,469

46. Lizanecz, E., Pasztor E.T., Mohacsi, A., Papp, Z., Edes, I., Toth, A. Mistyping angiotensinogen M235T alleles. Hypertens. Res. 29, 197-201, 2006. 3,177

47. Molnar A, Toth A, Bagi Z, Papp Z, Edes I, Vaszily M, Galajda Z, Papp JG, Varro A, Szuts V, Lacza Z, Gero D, Szabo C. Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.Mol Med. 12,143-52, 2006. 2,708

48. Erdei N, Bagi Z, Edes I, Kaley G, Koller A. Hydrogen Peroxide Contributes to Constrictor Prostaglandin Mediated Enhanced Arteriolar Tone in Type 2 Diabetic Mice. Am J Physiol Heart Circ Physiol. 291(5), H2107-15, 2006. 3,724

49. Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A, Bagi Z. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res. 99, e12-e17, 2006. 9,854

50. Bagi Z, Hamar P, Kardos M, Koller A. Lack of flow mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice. Lupus. 15, 326-334, 2006. 2,366

51. Erdei N, Toth A, Pasztor ET, Papp Z, Edes I, Koller A, Bagi Z. High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. Am J Physiol Heart Circ Physiol. 291, H2107-H2115, 2006. 3,724

52. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 148, 696-702, 2006. 3,825

53. Lazar J, Braun DC, Toth A, Wang Y, Pearce LV, Pavlyukovets VA, Blumberg PM, Garfield SH, Wincovitch S, Choi HK, Lee J. Kinetics of penetration influence the apparent potency of vanilloids on TRPV1. Mol Pharmacol. 69, 1166-1173, 2006. 4,469

54. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 113, 1966-73, 2006. 10,940

55. N.S. Dhalla, M. Dent, P.S. Tappia, R. Sethi, J. Barta, R.K. Goyal: Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure. J Cardiovasc. Pharmacol. Ther. 11: 31-45, 2006. 1,000

56. Machackova J, Barta J, Dhalla NS. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.Can J Cardiol. 22, 953-68, 2006. 1,134

57. Chung, J.U., Kim, S.Y., Lim, J.O., Choi, H.K., Kang, S.U., Yoon, H.S., Ryu, H.C., Kang, D.W., Lee, J., Kang, B., Choi, S., Toth, A., Pearce, L.V., Pavlyukovets, V.A., Lundberg, D.J., and Blumberg, P.M α-Substituted N-(4-t-Butylbenzyl)-N’-[4-(methysulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists Bioorganic and Medicinal Chemistry 15(18):6043-6053, 2007. 2,624

58. Bagi Z., Erdei N., Papp Z., Édes I., Koller A. Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus. Pharmacological Reports 58, Suppl:52-56, 2007. 0,764

59. Edes IF, Czuriga D, Csanyi G, Chlopicki S, Recchia FA, Borbely A, Galajda Z, Edes I, Velden JV, Stienen GJ, Papp Z. The rate of tension redevelopment is not modulated by sarcomere length in permeabilized human, murine and porcine cardiomyocytes. Am J Physiol Regul Integr Comp Physiol. 293, R20-R29, 2007. 3,685

60. Pollesello P, Papp Z. The Cardioprotective Effects of Levosimendan: Preclinical and Clinical Evidence. J. Cardiovasc. Pharmacol. 50, 257-263, 2007. 1,625

61. Papp Z., Borbély A., Édes I. Változások a szív kontraktilis fehérjeszerkezetében diastolés szívelégtelenség során. Lege Artis Medicinae 17, 441-445, 2007. -

62. Hegedüs, E., Imre, L., Pataki, J., Lizanecz, E., Székvölgyi, L., Fazakas, F., Bacsó, Z., Tóth, A., Szabó, M., Seres, Z. and Szabó, G. Heteroduplex analysis using flow cytometric microbead assays to detect deletions, insertions and single-strand lesions. Cytometry: Part A (In press) 2007. 3,293

63. Erdei N, Bagi Z, Edes I, Kaley G, Koller A. H2O2 increases production of constrictor prostaglandins in smooth muscle leading to enhanced arteriolar tone in Type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 292(1):H649-56., 2007. 3,724

64 Toth J, Racz A, Kaminski PM, Wolin MS, Bagi Z, Koller A. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension. 49(3):563-8., 2007. 6,007

65. Fulop T, Jebelovszki E, Erdei N, Szerafin T, Forster T, Edes I, Koller A, Bagi Z. Adaptation of Vasomotor Function of Human Coronary Arterioles to the Simultaneous Presence of Obesity and Hypertension. Arterioscler Thromb Vasc Biol. 27(11), 2348-54, 2007. 6,883

66. Toth E, Racz A, Toth J, Kaminski PM, Wolin MS, Bagi Z, Koller A. Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, diminished NO and enhanced PGH2/TXA2 mediation. Am J Physiol Heart Circ Physiol. [Epub ahead of print], 2007 3,724

67. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 28(20):2539-50, 2007. 7,286


Az in extenso publikációk összesített impakt faktora (2000-2007): 255,274

Az in extenso publikációk összesített impakt faktora (2003-2007): 234,348

Book chapters in Hungarian:

• 1. Papp, Z., Édes I. (2000) A szív- és simaizomsejtek ingerületi folyamatai és celluláris Ca2+ anyagcseréje. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 17-89. szerk: Édes I., Golden Book Kiadó, Budapest
• 2. Édes, I., Papp, Z. (2000) A szívizom kontraktilitásának celluláris szabályozása fiziológiás és patológiás körülmények között. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 91-99. szerk: Édes I., Golden Book Kiadó, Budapest
• 3. Édes, I., Papp, Z. (2000) A pozitív inotrop szerek csoportosítása és elméleti jellemzése. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 99-108. szerk: Édes I., Golden Book Kiadó, Budapest
• 4. Édes, I., Papp, Z., Kristóf, É. (2000) A Ca2+-érzékenyítés elméleti alapjai. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 123-135. szerk: Édes I., Golden Book Kiadó, Budapest
• 5. Papp, Z. (2000) A Ca2+-csatornák jellemzése. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 143-166. szerk.: Édes I., Golden Book Kiadó, Budapest
• 6. Papp, Z. (2000) A Ca2+-csatornák működésének farmakológiai befolyásolása. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 166-173. szerk.: Édes I., Golden Book Kiadó, Budapest
• 7. Édes, I, Papp, Z. (2000) Szívelégtelenség és Ca2+. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 227-247. szerk.: Édes I., Golden Book Kiadó, Budapest
• 8. Édes I., Papp, Z. (2000) A Ca2+ anyagcserére ható gyógyszerek várható fejlesztési lehetőségei. In: A szív- és simaizom Ca2+-anyagcseréje: elmélet, klinikum. pp.: 249-252. szerk.: Édes I., Golden Book Kiadó, Budapest
• 9. Lizanecz E., Mohácsi A.: Molekuláris biológiai alapfolyamatok: Inflammáció. In: Atherosclerosis, Synergo Kiadó, Budapest, 2004, 115-118.